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Cartilage-hair hypoplasia (CHH) is a pleiotropic disease caused by recessive mutations in the RMRP gene that result in a
wide spectrum of manifestations including short stature, sparse hair, metaphyseal dysplasia, anemia, immune
deficiency, and increased incidence of cancer. Molecular diagnosis of CHH has implications for management, prognosis,
follow-up, and genetic counseling of affected patients and their families. We report 20 novel mutations in 36 patients
with CHH and describe the associated phenotypic spectrum. Given the high mutational heterogeneity (62 mutations
reported to date), the high frequency of variations in the region (eight single nucleotide polymorphisms in and around
RMRP), and the fact that RMRP is not translated into protein, prediction of mutation pathogenicity is difficult. We
addressed this issue by a comparative genomic approach and aligned the genomic sequences of RMRP gene in the
entire class of mammals. We found that putative pathogenic mutations are located in highly conserved nucleotides,
whereas polymorphisms are located in non-conserved positions. We conclude that the abundance of variations in this
small gene is remarkable and at odds with its high conservation through species; it is unclear whether these variations
are caused by a high local mutation rate, a failure of repair mechanisms, or a relaxed selective pressure. The marked
diversity of mutations in RMRP and the low homozygosity rate in our patient population indicate that CHH is more
common than previously estimated, but may go unrecognized because of its variable clinical presentation. Thus, RMRP
molecular testing may be indicated in individuals with isolated metaphyseal dysplasia, anemia, or immune
dysregulation.
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PLoS Genet 1(4): e47.
Introduction
Cartilage-hair hypoplasia (CHH; MIM#250250) is a pleio-
tropic disease involving different organs and tissues. Its most
frequent clinical manifestations are short-limb dwarﬁsm with
metaphyseal dysplasia, joint laxity, ﬁne and sparse hair,
anemia, and immune deﬁciency [1–4], but Hirschsprung
disease, impaired spermatogenesis, and malignancies (partic-
ularly leukemias, lymphomas, and skin cancer) also occur at
increased frequency [5–8].
Mutations in RMRP, a gene encoding an RNA component
of the mitochondrial RNA processing ribonuclease (RNase
MRP) [9], were found to be responsible for CHH [10,11].
Among the known functions of RNase MRP are pre-rRNA
processing in the nucleolus and cleavage of RNA primers
necessary for DNA replication in the mitochondrion; but it is
likely that the RNA molecule coded by RMRP has other yet-
unidentiﬁed functions [12–18]. Forty-two different mutations
have been reported so far in 91 Finnish, 47 non-Finnish
Caucasian, and two Japanese families [11,19–22]. Given the
clinical and radiographic variability of CHH, molecular
diagnosis is important both for appropriate counseling and
for allowing relevant preventive measures. However, because
the RMRP RNA is not translated into a protein, it is difﬁcult
to evaluate the pathogenicity of a sequence variant. More-
over, the small RMRP gene (coding region of 265 base pairs
[bp]) has two remarkable features: a very high density of
single nucleotide polymorphisms (SNPs) [19,20,22] and an
extensive series of allelic, putatively pathogenic variants. For
this reason, molecular diagnosis and genetic counseling are
particularly difﬁcult.
We report here yet another series of 20 novel RMRP
mutations in CHH; more importantly, we show that RMRP
pathogenic mutations, but not SNPs, occur in nucleotides
conserved in the entire mammalian class. The implications of
these ﬁndings in connection with the wide clinical spectrum
of CHH are discussed.
Results
Mutations and Polymorphisms in CHH Patients
We performed mutation analysis of the RMRP gene in 36
patients with suspected CHH. Clinical data are summarized
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in Table 1. Twelve patients had only skeletal manifestations
of the disease during infancy and childhood, 11 patients had
also severe immune deﬁciency, whereas 13 patients had an
intermediate phenotype including skeletal dysplasia and at
least one extra-skeletal manifestation: recurrent infections
and/or subclinical immune deﬁciency, anemia and/or leuco-
penia, autoimmune manifestations, hair hypoplasia (deﬁned
as thin hair, often lightly colored, and rarely needing a
haircut), or Hirschsprung disease.
Thirty probands were found to be compound hetero-
zygotes for putative pathogenic variants (Table 1), whereas
the six remaining probands were true homozygotes for a
known pathogenic mutation (see below). We identiﬁed 20
previously unreported, putatively pathogenic mutations; ﬁve
of them are located in the promoter region and 15 in the
transcribed region. Table 2 details all RMRP mutations
reported to date and their localization, as well as the number
of reported affected families.
We identiﬁed ﬁve new insertions/duplications of 8 to 32 bp
localized in the last 25 nucleotides of the promoter region 59
to the transcription initiation site (Tables 1 and 2). All
duplications/insertions in the promoter region result in an
increased distance between the TATA box and the tran-
scription initiation site. This type of mutation was always
found in compound heterozygosity with a single nucleotide
mutation in the transcribed region and never homozygous or
in compound heterozygosity with another promoter dupli-
cation/insertion.
Among all mutations located within the transcribed region,
six are duplication/insertions of 1–17 nucleotides, one is a 2-
bp deletion, and the remaining variants are single nucleotide
changes (Table 2). Mutations in the transcribed region are
located throughout the RNA molecule (Figure 1; Table 2),
with no preference in any of the different structural domains.
Among the 39 single nucleotide mutations in the transcribed
region, 12 are located at nucleotides not involved in base-
pairing in the secondary structure of the RNA molecule
(Figure 1; Table 2) [18,23,24]. None of the 20 new putative
pathogenic mutations reported here were found in 100 non-
Finnish Caucasian controls.
The different parental origin of mutations in compound
heterozygote patients was conﬁrmed in 23 out of 24 families
for which parental DNA was available. In family 27 (Table 1),
mutation g.248C.T was carried by the father, whereas the
g.127G.A change was not present in maternal DNA or in that
of two unaffected sons. Microsatellite marker analysis of the
region around RMRP in this family (Figure S1) showed that
the same maternal allele is carried by the affected child and
by one of the healthy siblings, suggesting that g.127G.A is a
de novo mutation in this patient, occurring on the maternal
allele. However, maternal germinal mosaicism could not be
excluded.
Unlike in the Finnish/Amish population, only ﬁve patients
(24, 25, 31, 32, and 36 in Table 1) were homozygous for the
g.70A.G CHH mutation. One patient (34 in Table 1) was
homozygous for another known pathogenic mutation
(g.261C.T). No parental consanguinity was reported in our
sample.
We have previously identiﬁed seven frequent SNPs within
and around RMRP and four rare variants (Table 3) [19]. In a
Japanese control population (130 alleles), four other rare
sequence changes (g.36T.G, g.55–56insC, g.162C.T, and
g.172C.T) have been reported [22]. These variants were
found in controls only in heterozygosity and therefore their
neutrality is not proven. One more polymorphism has been
identiﬁed in the present study: g.127G.C. This variant was
found in 1% of non-Finnish Caucasian controls (two
chromosomes out of 200) and observed in one control
individual in proven compound heterozygosity with a known
pathogenic mutation (g.70A.G) (trans phase conﬁrmed by
parental DNA testing).
Sequence analysis of 100 controls did not detect any
putative pathogenic mutation (newly identiﬁed and previ-
ously described).
Comparative Genomic Analysis of RMRP
To address the signiﬁcance of sequence changes identiﬁed
in humans, we compared the human RMRP gene against a set
of orthologous sequences from mammalian species covering
Classes I, II, III, and IV of the Eutherians [25], the
Metatherians, and the Monotremes. We successfully PCR
ampliﬁed and sequenced the RMRP transcript regions from
genomic DNA of green monkey (Cercopithecus aethiops), ring-
tailed lemur (Lemur catta), brush-tailed porcupine (Atherurus
africanus), rabbit (Oryctolagus cuniculus), pig (Sus scrofa), cat (Felis
catus), white-toothed shrew (Crocidura russula), nine-banded
armadillo (Dasypus novemcinctus), African elephant (Loxodonta
africana), and tammar wallaby (Macropus eugenii) and aligned
them to human and mouse RMRP (Figure 2). The promoter
region of the gene was ampliﬁed from white-toothed shrew
(Cr. russula), brush-tailed porcupine (A. africanus), rabbit (Ory.
cuniculus), green monkey (Ce. aethiops), ring-tailed lemur (Le.
catta), cow (Bos taurus), and African elephant (Lo. africana)
(Figure 3).
The multiple species alignment of the RMRP transcribed
region showed that 23 putative pathogenic mutations out of
29 are located in strongly conserved nucleotides (same
nucleotide in at least 11 out of 12 species) (Figure 2). In
contrast, the three polymorphisms located within the coding
region (positions g.127, g.156, and g.177) are located in non-
conserved nucleotides. Similarly, multiple sequence align-
ment of the promoter region from 80 to the transcription
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Synopsis
Cartilage-hair hypoplasia is a genetic condition named after two of
its most conspicuous features, short bones and sparse hair, but it
affects blood-forming tissues, immune system, and intestine. It is
caused by sequence mutations in RMRP, a small gene that codes for
a structural RNA component of an RNAse complex whose biological
functions have been elusive so far. The small RMRP gene carries a
surprisingly high number of sequence variations, and because its
transcript is not translated into protein and its function in the cell is
still unclear, distinction between harmless variants and disease-
causing mutations (more than 60 have been found so far by the
authors and others) is difficult. The authors have sequenced the
RMRP gene in several species covering the whole class of mammals
and found that the gene is remarkably conserved between species.
Interestingly, mutations occurring in conserved (probably function-
ally important) regions of the gene appear to be disease-producing,
whereas those occurring in regions where evolution is more relaxed
seem to be harmless variants. These results will help in counseling
affected individuals and their families, and may lead to the discovery
of the real function of this mysterious gene.
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initiation site showed that only one out of four poly-
morphisms in this region is located in a conserved position
(Figure 3). Three out of four examined rare variants also
affect non-conserved nucleotides (g.24, g.36, and g.162)
(Figures 2 and 3).
Discussion
RMRP Structure and Mutations
The RMRP gene encodes a non-translated RNA that forms
a cage-shaped structure in the core of the ribonuclease
enzymatic complex. Although initially isolated in the mito-
chondrion, the enzyme is predominantly localized in the
nucleolus [26]. Different protein subunits bind to speciﬁc
domains of the RNA secondary structure [18,24,27–29]. The
most recent model of protein–RNA interactions of RNase
MRP [29] shows that some regions of the RNA molecule are
critical for protein binding (Figure 1). The P3 domain
(nucleotides 22–66) is involved in direct binding of several
protein subunits (hPop1, hPop4, Rpp20, and Rpp25)
[24,27,29]. This region contains also the nucleolar localization
signal region (nucleotides 23–62), previously reported as
muta t ion f ree [20 ] excep t fo r one in se r t ion
(g.57insTTCCGCCT), which did not change the signal se-
quence. We observed three novel mutations (g.35C.T,
g.40G.A, and g.45_53dupTGTTCCTCC) in the nucleolar
localization signal region. In the P3 domain mutation,
g.63C.T is recurrent and was observed in ﬁve unrelated
families in this study: four of them are of Dutch origin and
two of them share the same [g.63C.T]þ [g.70A.G] genotype
(Table 1); furthermore, in all four patients, g.63C.T
segregates with the Finnish haplotype (data not shown),
suggesting a possible common origin of the mutation.
Nucleotide 70 maps just after the end of the P3 domain in a
conserved region, which can form, in yeast, a 9-bp duplex
with 5.8S rRNA [17], suggesting a possible role in small rRNA
processing. The Finnish/Amish founder mutation, g.70A.G,
was found in 18 out of 72 chromosomes in our series of
patients. This frequency (26%) is far lower than the 48%
reported for non-Finnish populations [20]. It has been shown
that this mutation results from enrichment in an isolate
population and is thus not a mutational hotspot [30].
Another recurrent mutation in our series is g.4C.T,
identiﬁed in ﬁve of the studied families; it is not associated
with a speciﬁc haplotype (data not shown), suggesting a
multiple origin of the mutation. The other mutations are
located throughout the RNA molecule, and no clear
genotype-phenotype correlation could be recognized. Phe-
notypes were different in patients with the same genotype, as
previously reported for g.70A.G homozygote patients in
several Finnish studies [5,11].
Compound heterozygosity for a duplication/insertion in
the promoter region and a single nucleotide change in the
transcribed region occurs frequently: ten out of 36 families in
our sample, and seven out of 44 families in previous reports
[20]. Duplication/insertions in the promoter region have
never been reported in the homozygous state or in
compound heterozygosity with another mutation located
within the promoter region, either in our series or in
previous works [11,19,20,22]. Because RMRP is transcribed
by RNA polymerase III [18], the distance between the TATA
box and the transcription initiation site is critical for efﬁcient
transcription [31]. It has been found that duplications/
insertions in this region cause reduced quantity of transcript
[11]; the fact that no patient has been found to be
homozygous or compound heterozygous for such mutations
may indicate that the mutations are phenotypically lethal.
Thus, it appears that having drastically reduced amounts of
RMRP RNA, albeit of normal structure, is more deleterious
than having normal amounts of RMRP RNA containing
subtle structural changes.
Both the abundance of SNPs and the number and diversity
of pathogenic mutations in RMRP are remarkable and at
odds with the high conservation of the RMRP gene through-
out species. It is unclear at present whether the RMRP gene is
affected by a particularly high incidence of point mutations,
or whether there is reduced efﬁciency of DNA repairing
mechanisms speciﬁcally for the RMRP gene.
In the background of this mutational heterogeneity, we
observed in our patient population a rarity of parental
consanguinity and a low incidence of homozygosity for any
given mutation. The known inverse relationship between
parental consanguinity rate and frequency of a recessive
disease suggests that CHH is relatively common among
recessive diseases. Precise data on the incidence of CHH
outside Finland are lacking, and direct ascertainment is
difﬁcult because of the variable clinical expression.
Comparative Genomics
In molecular diagnosis of CHH, the deﬁnition of criteria of
pathogenicity for any given mutation is a key issue. Because
RMRP is not translated into protein, any prediction of the
consequences of a nucleotide change is difﬁcult. Correct
segregation of mutations in the families and absence of
mutations in controls are two commonly used criteria. Other
suggested criteria are evolutionary conservation of nucleo-
tides involved in CHH-associated mutations and involvement
in base-pairing in the secondary structure model [19]. Several
mutations that co-segregate with the disease in multiple
unrelated families with CHH do not map in base-pairing
positions (Figure 1, Table 2). The best example is g.70A.G,
the most frequent pathogenic allele worldwide, but 12 other
putatively pathogenic mutations are also located in non-
paired nucleotides of the RNA molecule. Thus, this criterion
appears to be of limited usefulness in deﬁning pathogenicity.
Conservation through species, instead, is strongly associated
with putative pathogenic mutations. Previously reported
multiple sequence alignments [23,32] took into account
organisms that were phylogenetically quite distant, and did
not examine the promoter region of the gene. We aligned the
promoter and transcribed region of RMRP from multiple
placental and one marsupial mammal. Our analysis shows
that putative pathogenic CHH-associated mutations involve
strongly conserved nucleotides (23 out of 29). Furthermore,
Homozygous alleles are shown in boldface. ,, indicates ‘‘much less than.’’
aDegree of metaphyseal dysplasia:þ indicates shortening of long bones and metaphyseal changes clearly present;
þþ indicates bowed, shortened long bones, marked metaphyseal cupping and striations, typical phalangeal
epiphyseal changes;  indicates shortening of long bones, no clear signs of metaphyseal dysplasia.
bDegree of hair hypoplasia: þ indicates thin hair, often lightly coloured, rarely needing an haircut;  indicates the
condition is absent.
cDegree of immune deficiency: þ indicates recurrent infections; þþ indicates severe immune deficiency with
opportunistic infections;  indicates the condition is absent.
dDegree of hematological abnormalities:þ indicates anemia and/or leucopenia;þþ indicates severe anemia and/or
severe leucopenia.
eHirschsprung disease: þ indicates the disease is present;  indicates the disease is absent.
fBone marrow transplantation was performed because of severe immune deficiency and anemia.
DOI: 10.1371/journal.pgen.0010047.t001
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positions corresponding to SNPs are mainly non-conserved,
both in the promoter and in the transcribed region (nine out
of 11, including rare variants).
We noticed two different changes at position 127, the
mutation g.127G.A, associated with CHH in two different
families, and the polymorphism g.127G.C, found in 1% of
non-Finnish Caucasian controls. This nucleotide is only
partially conserved through species, being 127C in Xenopus
and 127A in yeast [23,32]. In our alignment, armadillo has
127A whereas all the other placentals and wallaby have 127G.
Interestingly, we could document a de novo g.127G.A
transition in family 27 (Figure S1), indicating a possible
mutational hot spot at this position. Similarly at nucleotide
position 182, there are three different RMRP mutations in
CHH patients, g.182G.T, g.182G.C, and g.182G.A; the latter
was also observed de novo in a Japanese family [22].
Among all RMRP variants found in controls (Table 3), eight
single nucleotide changes are certainly neutral polymor-
phisms; the other nine variants were found in controls by us
and others only in heterozygosity and are therefore not
certainly neutral. Interestingly, the majority of rare variants
affect non-conserved nucleotides (Figures 2 and 3), suggesting
that they represent rare polymorphisms rather than patho-
genic mutations. In conclusion, our observations further
validate the role of phylogenetic footprinting in assessing
pathogenicity.
CHH Phenotypic Spectrum
CHH is both pleiotropic, with potential involvement of
different organs, and variable in its clinical severity. Skeletal
manifestations are characterized by metaphyseal dysplasia of
variable degree; extra-skeletal manifestations are sparse hair,
anemia, leucopenia, immune deﬁciency, Hirschsprung dis-
ease, and other possible organ involvement (endocrine,
autoimmune, and digestive) including malignancies. All
patients in our sample were ascertained because of short
stature and some degree of skeletal changes. We reviewed
personally all available radiographs and selected for those
patients who had the typical pattern of phalangeal and
metaphyseal striations, the degree of which can be variable.
We then separated patients in our sample into three arbitrary
groups: approximately 33% (12 out of 36) with short stature
and skeletal manifestations only; approximately 30% (11 out
of 36) with short stature and severe immune deﬁciency and/or
anemia; and approximately 36% (13 out of 36) with skeletal
dysplasia and at least one extra-skeletal manifestation, whose
immunological and hematological abnormalities were sub-
clinical or caused only mild clinical symptoms. The severity of
skeletal manifestations did not correlate with the severity of
extra-skeletal disturbances. Indeed, two patients with severe
immune deﬁciency had short stature but only very mild
changes on skeletal survey (Table 1). Thus, the spectrum of
CHH phenotypes is wide, ranging from isolated metaphyseal
dysplasia to severe immune deﬁciency associated with short
stature of variable degree. If at one end of the spectrum there
are several patients with only skeletal manifestations of the
disorder (skeletal variant) [19,33], we might also expect, at the
opposite end of the spectrum, CHH patients with anemia/
leucopenia/immune deﬁciency and normal stature. Although
all patients we had studied were short at the time of diagnosis,
not all of them were short at birth, indicating that prenatal
growth can be normal. Normal birth length was documented
in four patients who later developed clear skeletal signs of the
disease and no immunologic abnormalities.
The presence of hair hypoplasia is often associated with
other extra-skeletal manifestations: Seven patients out of
nine with this characteristic had also immunological anoma-
lies and/or Hirschsprung disease. The absence of hair changes
and of hematological/immunological involvement should not
exclude CHH from the differential diagnosis of a short child
with metaphyseal dysplasia. Short ﬁngers and cone-shaped
phalangeal epiphyses are a very sensitive marker for CHH;
our data indicate that molecular testing for RMRP mutations
should be considered in all unclear metaphyseal dysplasias.
Long-term follow-up will clarify whether patients with RMRP
mutations, but only skeletal signs at diagnosis, are at
increased risk of malignancy like those with immune
deﬁciency. Indeed, patient 36 (Table 1) had short stature
with skeletal dysplasia, but was otherwise healthy until
developing non-Hodgkin lymphoma in the fourth decade of
life.
Hirschsprung disease was diagnosed in four patients out of
Figure 1. RMRP Gene Product
The RNA molecule of the human RNase MRP complex is shown
according to the model of Welting et al. [29]. Nucleotides affected by
mutations (single nucleotide changes) are in red; polymorphisms and
rare variants are in blue. Insertion/duplication/deletions are indicated as
red (mutations) or blue (putative polymorphisms) arrows. Regions of
base-pairing are indicated as gray boxes. The P3 domain (nucleotides
22–66) is shaded.
DOI: 10.1371/journal.pgen.0010047.g001
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Table 2. RMRP Variants: 20 New Putative Pathogenic Mutations and Review of Reported Mutations
RMRP Mutation Localization in
the RNA Molecule
Base-Pairing
Positiona
FamiliesObserved
In [Reference No.]
1 g.20insTCTGTGAAGCTGGGGAC PR — 1 Nakashima et al. [22]
2 g.23_15dupTACTCTGTG PR — 1 Present paper
3 g.23_14dupTACTCTGTGA PR — 3 Ridanpaa et al. [11], Ridanpaa et al. [20], present paper
4 g.20_14dupTCTGTGA PR — 2 Ridanpaa et al. [20], present paper
5 g25_11tripACTACTCTGTGAAGC PR — 1 Ridanpaa et al. [11], Ridanpaa et al. [20], present paper
6 g.22_10dupACTCTGTGAAGCT PR — 1 Present paper
7 g.25_10tripACTACTCTGTGAAGCT PR — 1 Present paper
8 g.7_1insCCTGAG PR — 1 Ridanpaa et al. [11], Ridanpaa et al. [20]
9 g.14_7dupAAGCTGAG PR — 1 Ridanpaa et al. [20]
10 g.16_7dupTGAAGCTGAG PR — 1 Ridanpaa et al. [20]
11 g.4insGGACGTGGTT PR — 1 Ridanpaa et al. [20]
12 g.25_5dupACTACTCTGTGAAGCTGAGGA PR — 1 Present paper
13 g.20_4dupTCTGTGAAGCTGAGGAC PR — 2 Ridanpaa et al. [11], Ridanpaa et al. [20], present paper
14 g.14_3dupAAGCTGAGGACG PR — 1 Bonafe´ et al. [19]
15 g.14_1dupAAGCTGAGGACGTG PR — 1 Ridanpaa et al. [20]
16 g.8_1dupAGGACGTG PR — 1 Present paper
17 g.15_2dupGAAGCTGAGGACGTGGT TR-59end — 1 Nakashima et al. [22]
18 g.7_3dupGGACGTGGTT TR-59end — 1 Ridanpaa et al. [20]
19 g.4C.T TR, P1 Yes 6 Ridanpaa et al. [20], present paper
20 g.35C.T TR, P3 No 1 Present paper
21 g.40G.A TR, P3b Yes 1 Present paper
22 g.45_53dupTGTTCCTCC TR, P3 — 1 Present paper
23 g.57_64dupTTCCGCCT
(previously called 57insTTCCGCCT)
TR, P3 — 1 Ridanpaa et al. [20]
24 g.63C.T TR, P3a Yes 7 Ridanpaa et al. [20], Kuijpers et al. [21], present paper
25 g.64T.C TR, P3a Yes 1 Present paper
26 g.70A.G TR No .90 Ridanpaa et al. [11], Bonafe´ et al. [19], Ridanpaa et al. [20], present paper
27 g.79G.A TR, P4 Yes 1 Ridanpaa et al. [20]
28 g.93G.C TR No 1 Present paper
29 g.92_93insA TR — 1 Present paper
30 g.94_95delAG TR — 1 Ridanpaa et al. [20]
31 g.97G.A TR, P8 Yes 1 Present paper
32 g.96_97dupTG TR, P8 — 3 Ridanpaa et al. [11], Ridanpaa et al. [20], present paper
33 g.118A.G TR Yes 1 Ridanpaa et al. [20]
34 g.126C.T TR, P12 Yes 3 Ridanpaa et al. [20], present paper
35 g.127G.A TR, P12 Yes 2 Present paper
36 g.146G.A TR Yes 2 Ridanpaa et al. [20]. present paper
37 g.146G.C TR Yes 1 Present paper
38 g.152A.G TR No 1 Ridanpaa et al. [20]
39 g.154G.T TR Yes 1 Ridanpaa et al. [20]
40 g.180G.A TR, P12 Yes 2 Ridanpaa et al. [20]
41 g.182G.C TR, P12 Yes 2 Ridanpaa et al. [20]
42 g.182G.T TR, P12 Yes 1 Present paper
43 g.182G.A TR, P12 Yes 1 Nakashima et al. [22]
44 g.193G.A TR No 4 Ridanpaa et al. [20], present paper
45 g.195C.T TR No 6 Ridanpaa et al. [20], Bonafe´ et al. [19], present paper
46 g.195insT TR — 1 Kuijpers et al. [21]
47 g.211C.G TR No 3 Ridanpaa et al. [20]
48 g.213C.G TR Yes 1 Present paper
49 g.214A.T TR Yes 1 Ridanpaa et al. [20]
50 g.218A.G TR No 1 Nakashima et al. [22]
51 g.220T.C TR, P19 Yes 2 Present paper
52 g.230C.T TR, P19 Yes 1 Ridanpaa et al. [20]
53 g.236A.G TR No 1 Ridanpaa et al. [20]
54 g.238C.T TR No 4 Ridanpaa et al. [20], Bonafe´ et al. [19], present paper
55 g.242A.G TR No 3 Ridanpaa et al. [20], present paper
56 g.243C.T TR, P4 Yes 1 Ridanpaa et al. [20]
57 g.244G.A TR, P4 Yes 1 Present paper
58 g.248C.T TR, P4 Yes 1 Present paper
59 g.260C.G TR, P1 Yes 1 Present paper
60 g.261C.T TR, P1 Yes 1 Ridanpaa et al. [20], present paper
61 g.262G.T TR, P1 Yes 13 Ridanpaa et al. [20]
62 g.264C.A TR No 1 Ridanpaa et al. [20]
The 20 new putative pathogenic mutations are in boldface.
Nucleotide numbering: þ1 is the G at the transcription initiation site; nucleotides 59 toþ1 are numbered 1, 2, etc.; there is no base zero.
P3 is the P3 domain (nucleotides 22–66); P1, P2, P3a, P3b, P4, P8, P9, P12, are P19 are the helices involved in direct protein binding according to the model of Welting et al. [29]. (See also Figure 1.)
a
‘‘Yes’’ indicates that the nucleotide is involved in base-pairing in the secondary structure of the RNA molecule; ‘‘No’’ indicates that the nucleotide is not involved in base-pairing.
PR, promoter region, between the TATA box and the transcription initiation site; TR, transcribed region.
DOI: 10.1371/journal.pgen.0010047.t002
PLoS Genetics | www.plosgenetics.org October 2005 | Volume 1 | Issue 4 | e470449
RMRP Mutations in Cartilage-Hair Hypoplasia
36 (11%), a frequency similar to that reported for Finnish
patients (9%) [7]. As previously suggested [7], Hirschsprung
disease is associated with severely affected patients (Table 1).
Three patients in our series were reported to have growth
hormone (GH) deﬁciency. Previous studies showed that low
IGF-1 levels correlate, in CHH patients, with reduced
erythropoiesis [34], but true GH deﬁciency, deﬁned as
insufﬁcient response to GHRH (growth hormone-releasing
hormone) stimulation, was never demonstrated [35]; more-
over, GH treatment has proven to be of little value in CHH
patients [36], as well as in other skeletal dysplasias [37,38].
Because the biochemical demonstration of GH deﬁciency is
difﬁcult and dysregulation of the GH-IGF axis has previously
been observed in CHH patients, we would consider these data
with caution. In addition, other subclinical endocrine
abnormalities seem to occur in CHH patients: Abnormal
thyroid function was found in three patients in this study.
The association of hypobetalipoproteinemia and CHH
(patient 10 in Table 1) has not been previously described. As
clinical symptoms of hypobetalipoproteinemia are often not
evident in childhood, it is possible that this abnormality is not
frequently tested in CHH patients. However, it is unclear
whether hypobetalipoproteinemia is primary in this patient,
or secondary to subclinical malabsorption. Some clinical
manifestations in this CHH family overlap with Shwachman-
Diamond syndrome (SDS; MIM#260400) [39], a disease
characterized by pancreatic exocrine insufﬁciency, hemato-
logical dysfunction, and skeletal abnormalities, which is in the
differential diagnosis of CHH. Interestingly, the gene causing
SDS, SDBS, plays a role in RNA metabolism [40], suggesting a
possible pathogenetic mechanism common to CHH and SDS.
Intestinal malabsorption has been described in CHH [41–43],
also in association with celiac disease [44]. Although some
instances may be explained by opportunistic bowel infec-
tions, it is possible that enteropathy is another rare
manifestation of CHH pleiotropism. However this association
in single cases may also be caused by chance alone.
Autoimmune disorders were present in four patients in our
series. Previous reports suggested an autoimmune mechanism
underlying the anemia [45,46] and neutropenia [47] in some
CHH patients. There is no evidence of autoimmune anemia
in most CHH patients, but it is possible that immune
Table 3. RMRP Polymorphisms and Other Rare Variants
Category Polymorphism or Variant Localization in
the RNA Molecule
Base-Pairing
Positiona
Number of
Control
Chromosomes
Reference
RMRP polymorphisms 1 g.58T.C PR — 70 out of 200 Present paper, Bonafe´ et al. [19],
Ridanpaa et al. [20], Nakashima et al. [22]
2 g.56A.G PR — 31 out of 200 Present paper, Bonafe´ et al. [19],
Nakashima et al. [22]
3 g.48C.A PR — 102 out of 200 Present paper, Bonafe´ et al. [19],
Ridanpaa et al. [20], Nakashima et al. [22]
4 g.6G.A PR — 31 out of 200 Present paper, Bonafe´ et al. [19],
Nakashima et al. [22]
5 g.127G.C TR, P12 Yes 2 out of 200 Present paper
6 g.156G.C TR Yes 31 out of 200 Present paper, Bonafe´ et al. [19],
Nakashima et al. [22]
7 g.177C.T TR No 31 out of 200 Present paper, Bonafe´ et al. [19],
Nakashima et al. [22]
8 g.*9T.C
(previously called 274T.C)
— 61 out of 200 Present paper, Bonafe´ et al. [19],
Ridanpaa et al. [20], Nakashima et al. [22]
Other RMRP variations 1 g.24C.G PR — 1 out of 200 Bonafe´ et al. [19]
2 g.36T.G TR, P3 No 1 out of 130 Nakashima et al. [22]
3 g.55_56insC TR, P3 — 1 out of 130 Nakashima et al. [22]
4 g.57_58insA TR, P3 — 1 out of 200 Bonafe´ et al. [19]
6 g.162C.T TR Yes 2 out of 130 Nakashima et al. [22]
7 g.172C.T TR No 1 out of 130 Nakashima et al. [22]
8 g.250C.T TR No 1 out of 200 Bonafe´ et al. [19]
9 g.*7T.C
(previously called 272T.C)
— 2 out of 200 Bonafe´ et al. [19]
Nucleotide numbering: þ1 is the G at the transcription initiation site; nucleotides 5’ to þ1 are numbered 1, 2, etc.; there is no base zero. Nucleotides 39 to the last translated base are numbered *1, *2, etc.
P3 is the P3 domain (nucleotides 22–66); P1, P2, P3a, P3b, P4, P8, P9, P12, and P19 are the helices involved in direct protein binding according to the model of Welting et al. [29]. (See also Figure 1.)
a‘‘Yes’’ indicates that the nucleotide is involved in base-pairing in the secondary structure of the RNA molecule; ‘‘No’’ indicates that the nucleotide is not involved in base-pairing.
PR, promoter region, between the TATA box and the transcription initiation site; TR. transcribed region.
DOI: 10.1371/journal.pgen.0010047.t003
Figure 2. Multiple Sequence Alignment of the RMRP Transcribed Region
The sequence alignment of 12 mammalian species (11 placental and 1 marsupial) of the RMRP transcribed region (from nucleotide g.28 to g.247 of the
human sequence) is shown. Putative pathogenic mutations are indicated as red boxes (single nucleotide changes) or red arrows (insertion/duplications/
deletions); polymorphisms and rare variants are indicated as blue boxes (single nucleotide changes) or blue arrows (insertion/duplications/deletions).
Conservation of nucleotides was analyzed for the single nucleotide substitutions (putative mutations or polymorphisms) included in the alignment
interval (from g.28 to g.247). Positions were considered as conserved if 11 out of 12 species had the same nucleotide.
DOI: 10.1371/journal.pgen.0010047.g002
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dysregulation favors the development of autoimmunity
against other organs and tissues in CHH.
Materials and Methods
Sample population. A total of 59 patients referred to our center for
short stature and skeletal changes were included in this study; of
these, 40 patients showed the typical pattern of phalangeal epiphyseal
changes, metaphyseal cupping and striations of CHH (as judged by
two or more of the radiographic experts among us: LB, SU, AZ, and
ASF), albeit to a variable degree; and 19 had radiological changes that
were considered not typical but still compatible with CHH. All 59
patients were tested for RMRP mutations by sequencing of the entire
RMRP coding sequence as well as promoter region. Twenty-three
patients tested negative (all 19 patients in the non-typical group, plus
four patients considered to have radiographic changes typical for
CHH), and 36 patients had mutations in RMRP. The patient material
was referred to us for non-commercial diagnostic help and accepted
under the research terms speciﬁed in the European Skeletal Dysplasia
Network program (http://www.esdn.org/) (for European patients) or
analogously, for non-European subjects. Appropriate informed
consent was obtained by the physicians in charge. The clinical data
and the radiographic features of each patient were evaluated before
molecular testing. The clinical data of the 36 unrelated patients with
CHH are summarized in Table 1.
Parental DNA was studied in 24 families. For the remaining 12
patients (patients 2, 7, 8 [adopted], 11, 21, 24 [homozygote], 25
[homozygote], 26, 31 [homozygote], 32 [homozygote], 35, and 36
[homozygote]), parental DNA was not available.
Molecular analysis of RMRP gene. Genomic DNA was extracted
from blood leukocytes according to standard methods; in one patient
(patient 5) genomic DNA was extracted from ﬁbroblasts because bone
marrow transplantation had been performed before the study.
Genomic DNA of 100 non-Finnish Caucasian control individuals
(German, Italian, British, French, Swiss, Australian, and Canadian)
has been studied to test for the presence or absence of all variants,
including new putative pathogenic mutations, previously reported
mutations, and putative polymorphisms.
The coding and promoter regions of the RMRP gene were
ampliﬁed from genomic DNA by PCR and analyzed by ﬂuorescent
bidirectional direct sequencing as previously described [19]. Each
variant was conﬁrmed by reampliﬁcation and resequencing. Trans
phase of mutations in 24 compound heterozygote patients was
veriﬁed by conﬁrming the presence of mutations in parental DNA .
Microsatellite marker analysis of the region around RMRP in
family 27 was performed with the ABI Prism Linkage Mapping Set
version 2.5 kit and protocol, in an ABI Prism 3100Avant automatic
sequencer (Applied Biosystems, Foster City, California, United
States).
Comparative genomics. Tissues or genomic DNA from the
following species were obtained from different sources (for details
see Table S3 of Dermitzakis et al. [48]): S. scrofa, F. catus, My. myotis, Cr.
russula, A. africanus, Ory. cuniculus, Ce. aethiops, Le. catta, D. novemcinctus,
Lo. africana, Ma. eugenii, Orn. anatinus, B. taurus. Pairs of oligonucleo-
tides were designed on human DNA sequences in highly conserved
regions between human and mouse to amplify either the promoter
(59-GCCACCAACTTTCTCACC-39 and 59-GGGACTTTCCCC-
TAGGC-39) or the transcribed region (59-GGCCTGTATCCTAGGC-
TACA-39 and 59-AGCCGCGCTGAGAATGAG-39) of the RMRP gene.
Conservation of single nucleotide substitutions was analyzed on
the multiple sequence alignments of the transcribed region (Figure 2)
and the promoter region from g.–80 to g.1 (Figure 3), based on the
number of species harboring the same nucleotide. We considered as
conserved the positions where at least 11 out of 12 species (in the
transcribed region) or eight out of nine species (in the promoter
region) had the same nucleotide.
Supporting Information
Figure S1. Microsatellite Marker Analysis of the Region around
RMRP in Family 27
The same maternal haplotype is carried by the affected child and by
one of the healthy siblings. Neither the mother nor the unaffected
sibling carry g.127G.A, suggesting that this mutation occurred de
novo in the affected individual (see also Table 1).
Found at DOI: 10.1371/journal.pgen.0010047.sg001 (378 KB PDF).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession num-
bers for the PCR-ampliﬁed RMRP sequences are CC935687,
CC935890, CC935995, CC936164, CC936319, CC936439, CC936561,
Figure 3. Multiple Sequence Alignment of the RMRP Promoter Region
The sequence alignment of the RMRP promoter region of nine mammalian species (from nucleotide g.80 to the transcription initiation site of the
human sequence) is shown. Polymorphisms and rare variants are indicated as blue boxes (single nucleotide changes); red arrows indicate pathogenic
insertions, and red lines indicate pathogenic duplications and triplications. Conservation of nucleotides was analyzed for the single nucleotide
substitutions (putative polymorphisms) included in the alignment interval (from g.80 to g.1). Positions were considered as conserved if eight out of
nine species had the same nucleotide.
DOI: 10.1371/journal.pgen.0010047.g003
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CC936652, and CC936711; the GenBank accession number for the
RMRP gene is M29916.
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Note Added in Proof
After submission of this manuscript, Thiel et al. identiﬁed four novel RMRP
mutations in three families affected by a very rare condition called anauxetic
dysplasia (MIM 607095) [49]. There is considerable phenotypic overlap of this
condition with CHH, although, interestingly, no immune dysregulation or hair
anomalies have been reported in this condition. According to our alignment,
two of the four reported mutations (g.111-112insACGTAGACATTCCT and g.90-
91AG.GC) are located in highly conserved regions (the other two mutations
are located out of the alignment). These data strengthen the value of the
evolutionary comparison approach in deﬁning pathogenicity of RMRP
mutations.
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